Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 0.44 |
| ▸ | TACR2 | P21452 | 1/20 | 0.44 |
| ▸ | TACR3 | P29371 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4024411 | 0.87 | TACR1 (0.52) | TACR1TACR2TACR3 | |
| SCHEMBL4021064 | 0.86 | TACR1 (0.61) | TACR1TACR2TACR3 | |
| SCHEMBL4021418 | 0.86 | TACR1 (0.40) | TACR1TACR2TACR3 | |
| SCHEMBL4023089 | 0.86 | TACR1 (0.61) | TACR1TACR2TACR3 | |
| SCHEMBL4030817 | 0.81 | TACR1 (0.44) | TACR1TACR2TACR3 | |
| SCHEMBL4029698 | 0.80 | TACR1 (0.57) | TACR1 | |
| Hydrochloric Acid SCHEMBL4023505 | 0.80 | TACR1 (0.43) | TACR1TACR2TACR3 | |
| SCHEMBL4031204 | 0.80 | TACR1 (0.40) | TACR1TACR2TACR3 | |
| Hydrochloric Acid SCHEMBL4029674 | 0.79 | TACR1 (0.56) | TACR1 | |
| Hydrochloric Acid SCHEMBL4023552 | 0.79 | TACR1 (0.39) | TACR1TACR2TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1338592-B1 | Novel 2-phenylpiperazine derivatives | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2009-01-21 | — | — | EP | claimed |
| EP-1338592-A1 | Novel 2-phenylpiperazine derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2003-08-27 | — | — | EP | claimed |
| EP-1338592-B1 | Novel 2-phenylpiperazine derivatives | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-6906074-B2 | 2-phenylpiperazine derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2005-06-14 | — | — | US | disclosed |
| US-20030166616-A1 | Novel 2-phenylpiperazine derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1338592-A1 | Novel 2-phenylpiperazine derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2003-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166616-A1 | Novel 2-phenylpiperazine derivatives | VIPR2, BDKRB2, TRPC5 | TACR1 11/4885TACR2 13/4885TACR3 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.